Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DMSQLZJ)

Drug Name	Nifurtimox DMSQLZJ
Synonyms	NIFURTIMOX; Lampit; Bayer 2502; 23256-30-6; BAY 2502; Nifurtimox [INN:BAN]; Nifurtimoxum [INN-Latin]; CCRIS 2201; EINECS 245-531-0; CHEBI:7566; C10H13N3O5S; 4-Thiomorpholinamine, 3-methyl-N-((5-nitro-2-furanyl)methylene)-, 1,1-dioxide; 4-((5-Nitrofurfurylidene)amino)-3-methylthiomorpholine-1,1-dioxide; 3-Methyl-N-[(5-nitro-2-furanyl)methylene]-4-thiomorpholinamine 1,1-dioxide; 3-Methyl-4-(5'-nitrofurylidene-amino)-tetrahydro-4H-1,4-thiazine-1,1-dioxide
Drug Type	Small molecular drug
Structure
Structure	3D MOL			2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

1 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Chagas disease	DIS8KNVF	IF53	Approved	[1]
------------------------------------------------------------------------------------

1 Phase 4 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Trypanosomiasis	DISUBO83	1D51-1F53	Phase 4	[2]
------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
2	ClinicalTrials.gov (NCT00906880) Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense HumanAfrican Trypanosomiasis (HAT) in the Meningo-encephalitic Phase. U.S. National Institutes of Health.